Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
November 1, 2021
November 1, 2021
MedinCell announces participation in the Jefferies London Healthcare Conference 2021
October 25, 2021
October 25, 2021
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
October 21, 2021
October 21, 2021
MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
September 10, 2021
September 10, 2021
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM